EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Lung organoids as emerging models in idiopathic pulmonary fibrosis research: Current applications, challenges, and future directions

Yuxin Jia, Wenxian Liu, Weifeng Tang, Silin Ou, Na Wang, Ming Dong, Ying Wei iD

Therapeutic Advances in Respiratory Disease · 2026-08 · 20

DOI: 10.1177/17534666261475569 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Therapeutic Advances in Respiratory Disease, online erschienen am 04.08.2026. Verfasst von Yuxin Jia und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Integrative Medicine, Huashan Hospital Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Idiopathic Pulmonary Fibrosis, Organoids, Lung. Die Arbeit nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Idiopathic pulmonary fibrosis (IPF) is a devastating lung disease with progressive, irreversible scarring and a median survival of approximately 3–5 years after diagnosis. Current therapies (nintedanib, pirfenidone) modestly slow progression but do not halt or reverse fibrosis, creating a critical therapeutic plateau and unmet need. Improved human-centric models are essential to dissect how genetic susceptibility and chronic epithelial exhaustion drive aberrant repair in IPF. Lung organoids, as three-dimensional (3D) constructs that recapitulate human lung architecture and cellular responses to pathological cues have increasingly been used as important human-relevant platforms for IPF research. In this review, we summarize recent advances in the application of lung organoids to IPF research, including disease modeling, mechanistic studies, and preclinical drug testing, and we discuss the potential and current limitations of patient-derived organoids (PDOs) in personalized medicine. We also outline ongoing efforts to improve these models through the incorporation of vascular, immune, and mechanical components, such as assembloids and lung-on-a-chip systems. Although important challenges remain, including maturation, standardization, and scalability, lung organoids may provide a valuable complementary platform for future IPF research and translational studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Idiopathic Pulmonary FibrosisOrganoidsLungHumansAnimalsPrecision MedicineMicrophysiological SystemsDisease ProgressionDrug Evaluation, Preclinical

Stichwörter der Autor:innen

Idiopathic Pulmonary Fibrosis (IPF)lung organoidspersonalized medicineprecision therapeutics

Autor:innen und Institutionen

  • Department of Integrative Medicine, Huashan Hospital Fudan University, Shanghai, China.
  • Institute for the Modernization of Traditional Chinese Medicine, Pu'er University, Pu'er, China.
  • Department of Respiratory Medicine, Second Affiliated Hospital of Yunnan University of Chinese Medicine, Kunming, China.
  • Department of Integrative Medicine, Children's Hospital of Fudan University, Shanghai, China.
  • Department of Rehabilitation Medicine, Gumei Community Health Center of Minhang District of Shanghai, Shanghai, China.
  • Institutes of Integrative Medicine, Fudan University, Shanghai, China.

ORCID-Profile: Ying Wei

Zitieren

APA

Jia, Y., Liu, W., Tang, W., Ou, S., Wang, N., Dong, M., & Wei, Y. (2026). Lung organoids as emerging models in idiopathic pulmonary fibrosis research: Current applications, challenges, and future directions. Therapeutic Advances in Respiratory Disease, 20. https://doi.org/10.1177/17534666261475569

Vancouver

Jia Y, Liu W, Tang W, Ou S, Wang N, Dong M, et al. Lung organoids as emerging models in idiopathic pulmonary fibrosis research: Current applications, challenges, and future directions. Therapeutic Advances in Respiratory Disease. 2026;20. doi:10.1177/17534666261475569

BibTeX
@article{Jia2026,
  author = {Jia, Yuxin and Liu, Wenxian and Tang, Weifeng and Ou, Silin and Wang, Na and Dong, Ming and Wei, Ying},
  title = {Lung organoids as emerging models in idiopathic pulmonary fibrosis research: Current applications, challenges, and future directions},
  journal = {Therapeutic Advances in Respiratory Disease},
  year = {2026},
  volume = {20},
  doi = {10.1177/17534666261475569}
}
Kostenlos starten →